14May 2016

Proactive Investors One2One forum – investor event

header-london

You are warmly invited to attend Proactive Investors’ One2One forum which is taking place on Thursday 19th May. Presenting companies will include Abzena (LON:ABZA), Allergy Therapeutics (LON:AGY),Sareum Holdings (LON:SAR) & Clinigen (LON:CLIN).

The evening will end with a complimentary bar and canapes, giving you the opportunity to speak with the directors and other investors.

Abzena (LON:ABZA- Market Cap £68 Million)

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise.

The company recently announced that the integration of two US companies acquired last year – PacificGMP and TCRS – is progressing well and the company expects both of these acquisitions to help fuel future growth.

CFO Julian Smith will be at the forum to outline how the company intends to drive growth going forwards

Allergy Therapeutics (LON:AGY – Market Cap £152 Million)

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.

The company’s results for 2015 revealed that it has gained market share across all of its markets and Allergy expects the double-digit revenue growth over the period to be sustained throughout 2016.

Chief Executive Officer Manuel Llobet will present an up-to-date investment case for Allergy Therapeutics to investors.

Sareum Holdings (LON:SAR – Market Cap: £21 million).

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at pre-clinical or early clinical trials stage.

The shares were given a boost recently as the cancer drug specialist received the green light for clinical trials of its lead candidate CCT725737. Studies on the drug in question have shown that it can boost the activity of relevant chemotherapies to combat lung, pancreatic and colon cancers.

Chief Executive Tim Mitchell will be at the forum to shed some more light on what this news could mean for the company over the long term.

Clinigen (LON:CLIN – Market Cap £602 Million)

Clinigen Group is a global pharmaceutical and services company with a combination of businesses focussed on providing access to personalised medicines.

Last month it announced a set of interim results which showed that operating profits grew by 74% to £23.5 million over the final 6 months of 2015, driven by the impact of recent acquisitions of Idis, a specialist in the supply of unlicensed medicines and Link Healthcare, which has become part of Clinigen’s managed access division.

Deputy CEO Shaun Chilton will be at the forum to outline what investors can expect from the company over the next twelve months and beyond.

Please arrive at 5:45pm to get yourself a seat and to allow for a prompt 6:00pm start. Each company has approximately 20 minutes to give a short presentation, followed by 10 minutes of Q&A.

The evening will end with a complimentary bar and canapes, giving you the opportunity to speak with the directors and other investors.

DETAILS: 
DATE: Thursday 19th May 2016
TIME: 5:45pm arrival for a prompt 6:00pm start
VENUE: Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB
ROOM: Charles Suite (1st floor)
MAP: See here for map
OTHER:

REGISTER:

Complimentary wine & canape reception

Click here to Register 



London South East Investment Forums

DON’T MISS OUT!
Subscribe To Our Newsletter
Be the first to get latest updates and exclusive content straight to your email inbox.
Stay Updated
Give it a try, you can unsubscribe anytime.
Get the week’s best articles right in your inbox
Subscribe
Join 15K subscribers